Blog Big Molecule Watch July 15, 2020

Samsung Biologics May Add Manufacturing Capacity at its Site in Korea

Samsung Biologics has announced that it may expand its manufacturing capacity at its site in Songdo, Incheon.  Launched in 2011, Samsung has three plants housing a total of 364,000 L of mostly stainless-steel bioreactor capacity that, according to Samsung’s CEO, will be fully utilized to capacity by 2022. Samsung’s CEO had previously said that “the company will prepare to add a fourth plant and new bio campus” to keep up with the momentum of biomanufacturing demand, and that the “addition of a fourth plant is a plan that is to be studied in the long run.”  According to the Nikkei Asian Review, Samsung closed over $1.5 billion worth of orders in the past three months, including a mix of biosimilar and novel antibodies.

 

The post Samsung Biologics May Add Manufacturing Capacity at its Site in Korea appeared first on Big Molecule Watch.